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Summary
Objectives:  To  set  out  good  practice  guidelines  for  locoregional  extension  assessment  of  squa-
mous cell  carcinoma  of  the  head  and  neck  (excluding  nasopharynx,  nasal  cavities  and  sinuses).
Materials  and  methods:  A  critical  multidisciplinary  review  of  the  literature  on  locoregional
extension  assessment  of  squamous  cell  carcinoma  of  the  head  and  neck  was  conducted,  applying
levels of  evidence  in  line  with  the  French  health  authority’s  (HAS)  literature  analysis  guide  of
January 2000.
Conclusion:  Based  on  the  levels  of  evidence  of  the  selected  articles  and  on  work-group  consen-
sus, graded  guidelines  are  set  out  for  clinical,  endoscopic  and  imaging  locoregional  extension
assessment  of  head  and  neck  cancer.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Clinical  assessment:  SFORL  guidelines
Complete  clinical  examination  of  the  oral  cav-
ity,  oropharynx,  laryngopharynx  and  neck  should  be
included  in  initial  staging  in  head  and  neck  cancer.
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n  head  and  neck  as  in  any  cancer,  initial  staging  is  crucial:
t  conﬁrms  diagnosis  (histology)  and  assesses  tumor  stage
local,  regional  and  any  metastatic  extension),  and  is  essen-
ial  for  TNM  staging  and  optimal  therapeutic  strategy.
It  was  decided  that  the  present  guidelines  should  concern
nitial  staging  of  head  and  neck  squamous  cell  carcinoma
xcluding  nasopharynx,  facial  sinus  and  nasal  cavity  cancer.
The  objective  was  thus  to  set  out  guidelines  for  locore-
ional  extension  assessment  of  squamous  cell  carcinoma  of
he  head  and  neck.
Therapeutic  strategy  further  involves  remote  exten-
ion  assessment  (notably  including  tracheobronchial  and
sophageal  endoscopy)  and  general  pre-treatment  assess-
ent,  dealt  with  in  separate  reports.
aterial and methods
he  present  guidelines  were  drawn  up  by  a  multidisciplinary
xpert  group  of  ENT  specialists  and  also  radiologists,  max-
llofacial  surgeons,  radiotherapists,  medical  oncologists,
athologists,  nuclear  medicine  specialists  and  anesthe-
iologists.  They  seek  to  specify  locoregional  extension
ssessment  based  on  a  critical  literature  analysis  and,  in
he  lack  of  ﬁrm  evidence,  to  establish  an  expert  consen-
us.  They  take  full  account  of  the  2012  French  Society  of
adiology  (SFR)  guidelines  [1].
The  individual  guidelines  were  graded  according  to  the
evel  of  evidence  of  each  underlying  literature  report.
ppendix  A  presents  the  levels  of  evidence  and  guide-
ine  grades,  following  the  French  health  authority’s  (HAS)
000  literature  analysis  and  guideline  grading  guide,  in  turn
nspired  by  the  Sackett  scoring  system.
linical  and  endoscopic  examination
eck  inspection  and  palpation  and  complete  examination  of
he  oral  cavity,  pharynx  and  larynx  provide  local  extension
ssessment  and  also  enable  investigation  of  any  synchronous
ucosal  location,  which  may  concern  the  entire  upper
erodigestive  tract  and  also  the  tracheobronchial  tree  and
sophagus.  Secondary  locations  must  be  explored  for  in  case
p
o
r(Grade  A)
f  alcohol  and  nicotine  intoxication,  which  is  the  prime
isk  factor  in  head  and  neck  cancer.  The  incidence  of  syn-
hronous  cancer  varies  between  reports:
2.4%  in  symptom-based  exploration  [2];
8.5%  in  systematic  panendoscopic  exploration  [3];
66  out  of  851  patients  (7.7%)  in  a  large-scale  retrospective
French  study  [4].
Metastatic  adenopathy  is  found  in  10  to  50%  of  cases  on
nitial  examination,  and  represents  an  important  prognostic
actor  [5].  Size,  mobility  and  location  (areas  I to  VI)  should
e  investigated  [6].
Endoscopic  assessment:  SFORL  guidelines
Endoscopy  under  general  anesthesia  should  be
performed,  associated  to  palpation,  biopsies  and  a
detailed  report  with  a  dated  drawing  and/or  photo-
graph  or  video.  (Grade  B)
Clinical  TNM  classiﬁcation  is  based  on  endoscopy,  ideally
erformed  under  general  anesthesia  if  not  contra-indicated.
echniques  vary  according  to  team  and  situation.  Surgeon-
nesthetist  teamwork  is  essential.  Assessment  indicates
esion  resection  possibilities,  and  exposure  options  are
etailed  for  possible  transoral  resection.  Possible  syn-
hronous  mucosal  locations  are  explored.  Biopsies  are  taken
rom  within  the  tumor,  outside  of  any  necrotic  or  ulcer-
ted  area,  and  samples  are  sent  for  analysis  accompanied
y  clinical  data.  If  possible,  a frozen  fragment  may,  with  the
atient’s  consent,  be  delivered  to  the  tumor  bank,  strictly
bserving  good  practice  rules  for  sampling  and  conservation.
SFORL  guidelines  for  cytology,  histology  and  HPV  explo-
ation  are  published  elsewhere.
Initial  staging  of  squamous  cell  carcinoma  of  the  oral  cavity,  lary
Human  papilloma  virus  (HPV):  SFORL  guidelines
HPV  exploration  should  not  be  systematic  in  absence
of  therapeutic  impact  (professional  consensus).
In  the  particular  cases  of  oropharyngeal  carcinoma
and/or  patients  without  alcohol/nicotine-related  risk
factors,  immunohistochemistry  with  anti-P16  antibody
is  an  option  for  epidemiological  purposes  (professional
consensus).
Role  of  vital  staining:  SFORL  guidelines
ENT-region  vital  staining  is  not  recommended  as  part
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Mof  initial  staging  in  head  and  neck  cancer  (Grade  A).
Toluidine  blue  (tolonium  chloride)  staining  associated  to
acetic  acid  has  been  described  essentially  for  oral  cavity
lesions,  whereas  Lugol  can  be  used  for  the  oral  cavity,  phar-
ynx  and  esophagus.  A  recent  systematic  review  [7]  found  no
solid  evidence  in  favor  of  diagnostic  aids  such  as  toluidine
blue  for  early  detection  of  oral  cavity  cancer.  New  controlled
randomized  cost/beneﬁt  studies  are  needed  to  assess  these
examinations  in  general  population  screening  [7].  Moreover,
being  applied  topically,  these  stains  do  not  allow  detection
of  submucosal  lesions  [7].
Role  of  novel  endoscopy  techniques:  SFORL  guide-
lines
Novel  endoscopy  techniques  such  as  autoﬂuores-
cence,  narrow-band  imaging  or  confocal  endomi-
croscopy  should  be  applied  in  research  protocols
(professional  consensus).
New  ‘‘bioendoscopy’’  techniques  based  on  tissue  compo-
sition  and  the  physical  properties  of  light  are  currently
under  evaluation.  Tissue  contains  endogenous  ﬂuorophores,
at  concentrations  varying  between  healthy  and  pathological
tissue;  excitation  induces  autoﬂuorescence.  Level  2  and  3
clinical  studies  reported  greater  sensitivity  with  autoﬂuo-
rescence  than  white-light  endoscopy  for  early  diagnosis  of
cancerous  and  precancerous  laryngeal  lesions;  associating
white  light  and  autoﬂuorescence  enhanced  diagnostic  per-
formance  [8].
Narrow  band  imaging  (NBI)  endoscopy  uses  a  series
of  emission  wavebands  speciﬁcally  selected  according  to
hemoglobin  absorption  spectra,  improving  visualization  of
microvascularization  and  tissue  micro-architecture.  It  has
been  recommended  for  early  diagnosis  of  cancerous  and
precancerous  head  and  neck  lesions,  of  the  larynx  but
also  the  pharynx  and  oral  cavity  [9].  Preliminary  studies
also  demonstrated  applications  in  determining  oncologic
resection  margins  and  exploring  for  the  primary  squamous
cell  carcinoma  in  precessive  metastatic  cervical  adenopa-
thy.  NBI  is  currently  associated  to  videoendoscopy,  and
considerably  improves  the  resolution  obtained  with  white
light.  Some  preclinical  and  in  vivo  pilot  studies  have  been
performed  in  the  oral  cavity  [10,11].
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Confocal  endomicroscopy  is  still  in  its  experimental
tages  in  ENT  oncology;  it  produces  in  vivo  cell-level  tissue
mages.  It  is  based  on  the  principles  of  confocal  microscopy,
roviding  virtual  optical  cross-sections  so  that  only  those
mages  showing  ﬂuorescence  in  a  given  optical  plane  may
e  recorded.
maging  assessment
Imaging  assessment:  SFORL  guidelines
Imaging  assessment  of  head  and  neck  carcinoma
requires  close  teamwork  between  clinician  and  imag-
ing  specialist,  with  rigorous  technique  (professional
consensus).
Information  transmission  should  also  enable  full  data
analysis  (various  analysis  windows,  possibility  of  high-
quality  multiplanar  reconstruction)  and  data  storage  in
a  picture  archiving  and  communication  system  (PACS)
(professional  consensus).
Possible  limitations  for  CT  or  MRI  and  contrast  medium
njection  should  be  examined  in  advance  and  discussed  with
he  radiologist.  Transmission  of  clinical  data  and  of  available
ndoscopy  and  pathology  results  is  essential  to  image  inter-
retation.  Exhaustive  head  and  neck  or  thoracic  CT  or  head
nd  neck  MRI  examination  should  therefore  be  performed
n  line  with  the  SFR  quality  guidelines  [1].  Depending  on
umor  location,  a  second  CT  acquisition  may  be  performed
nder  dynamic  maneuver:  in  phonation  for  laryngeal  tumor
taging;  with  Valsalva  maneuver  for  hypopharyngeal  tumor).
Imaging  oral  cavity  and  oropharynx  cancer:  SFORL
guidelines
Cervicothoracic  CT  should  be  performed  as  part  of
initial  staging  in  oral  cavity  and  oropharynx  cancer
(Grade  B).
MRI  is  the  most  effective  means  of  local  assessment
of  oral  cavity  and  oropharynx  cancer,  and  should  usually
be  associated  to  cervicothoracic  CT  (Grade  C).
CT  and  MRI  are  complementary  explorations  for
assessing  mandibular  invasion  (Grade  C).
MRI  is  sensitive  in  deep  lingual  tumor  extension
ssessment  on  gadolinium-enhanced  T1-weighted  and
2-weighted  sequences  [12]. Park  et  al.  reported  strong
orrelation  (Pearson  coefﬁcient,  0.94)  for  lingual  tumors
n  gadolinium-enhanced  fat-suppressed  T1-weighted
equences,  but  weaker  correlation  for  tonsillar  locations
13].
MRI  is  of  great  diagnostic  value  for  mandibular  invasion
14]. Van  Cann  et  al.,  however,  found  no  signiﬁcant  beneﬁt  of
RI  over  CT,  although  both  were  of  greater  diagnostic  value
han  panoramic  radiography  [15]. Imaizumi  et  al.  found  no
ifference  in  sensitivity  between  MRI  and  CT  in  exploring
andibular  invasion,  although  CT  was  much  more  speciﬁc
n  detecting  incipient  cortical  invasion  or  mandibular  canal
4 S.  Vergez  et  al.
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Cervical  extension  assessment:  SFORL  guidelines
Regional  lymph-node  extension  should  be  assessed
(from  skull  base  to  superior  mediastinal  oriﬁce)  as
part  of  the  local  extension  assessment,  using  contrast-
injected  cervicothoracic  CT  (Grade  B).
MRI  and  FDG-PET/CT  are  effective  in  lymph-node
extension  assessment,  but  should  not  be  the  ﬁrst-line
examinations  (Grade  C).
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nﬁltration;  they  also  stressed  the  high  false-positive  rate
n  MRI,  associated  with  inﬂammatory  dental  remodeling  or
xtraction  [16].
Imaging  laryngeal  and  pharyngeal  cancer:  SFORL
guidelines
Cervico-thoracic  CT  should  form  part  of  initial  stag-
ing  in  laryngeal  and  hypopharyngeal  cancer  (Grade  B).
Cervical  CT  with  dynamic  maneuvers  and  opti-
mized  contrast  enhancement  is  the  most  effective
examination  in  local  assessment  of  laryngeal  and
hypopharyngeal  cancer  (Grade  C).
Indications  for  MRI  are  exceptional  (professional
consensus).
CT  and/or  MRI  are  the  imaging  techniques  recommended
n  local  assessment  of  deep  tumor  volume  and  extension.
ome  authors  prefer  CT,  as  being  less  sensitive  to  movement
rtifacts  and  allowing  dynamic  maneuvers  and/or  thoracic
xploration  in  the  same  examination  step  [1].  In  laryngeal
nd  hypopharyngeal  locations,  CT  and  MRI  provide  detailed
natomic  study,  but  overestimate  local  invasion,  especially
n  the  glottis,  paraglottic  region  and  cartilaginous  structures
13.7  to  25%  discordance  with  histology)  [17—19]. Tumor  vol-
mes  as  contoured  on  CT  and/or  MRI  are  signiﬁcantly  greater
han  in  reality  or  on  ﬂuorodeoxyglucose  positron  emission
omography  (FDG-PET)  [20], while  superﬁcial  lateral  and
ubglottic  extension  are  underestimated  [20,21].
Multislice  helical  CT  provides  fast  multiplanar  analy-
is  of  pharyngolaryngeal  structures.  In  certain  anatomic
egions  (larynx,  piriform  sinus),  dynamic  phonation  or  Val-
alva  maneuvers  can  enhance  detection  sensitivity  (from  85
o  92%)  [22]. Some  authors  consider  that  complementary
cquisition  under  apnea  or  Valsalva  is  of  interest  only  for
xploration  of  the  glottis  [23].
MRI  provides  equally  detailed  anatomic  study,  but  is
onger  to  perform,  and  is  more  sensitive  to  movement
rtifacts,  notably  swallowing,  and  does  not  allow  dynamic
aneuver.  According  to  Becker  et  al.,  it  provides  better
umor  extension  assessment  within  cartilage  specimens,
ith  overall  sensitivity  of  92%  and  overall  speciﬁcity  of  82%
24].
Whichever  imaging  technique  (CT  or  MRI)  is  used,  there
s  consensus  as  to  the  difﬁculty  of  precisely  assessing
artilaginous  extension  and  the  need  for  strict  semiolog-
cal  criteria  in  both  CT  (associated  sclerosis,  osteolysis
nd  extra-laryngeal  extension)  and  MRI  (T1  hyposignal
n  invaded  cartilage,  with  T2  and  gadolinium-enhanced
1-weighted  hypersignal  indistinguishable  from  adjacent
umor)  [21,24—26].  FDG-PET,  while  giving  a  more  realistic
stimate  of  tumor  volume  [20], contributes  little  to  initial
taging  as  its  anatomic  resolution  is  currently  poorer  than
T  or  MRI  [27].
As a  complement  to  clinical  examination  in  initial  head
nd  neck  cancer  staging,  the  French  national  SFR  guidelines
ecommend  cross-sectional  imaging  to  explore  for  regional
ymph-node  invasion  [1].  Whatever  the  tumor  location,  cer-
ical  lymph-node  extension  should  be  assessed  in  the  same
tep  as  local  tumor  assessment  by  CT  (mean  sensitivity,
1%;  mean  speciﬁcity,  76%)  or  MRI  (mean  sensitivity,  81%;
r
c
o
6ean  speciﬁcity,  63%)  [28]. There  is  no  signiﬁcant  difference
etween  the  two  techniques  in  terms  of  diagnostic  value
28,29].  FDG-PET/CT  also  shows  sensitivity  (87—90%)  and
peciﬁcity  (87—90%)  as  good  as  or  better  than  CT  and/or  MRI,
lthough  the  difference  is  not  always  signiﬁcant,  and  the
ensitivity  of  FDG-PET  falls  to  50%  in  clinically  N0  patients
27,29—32].  Seitz  et  al.  found  no  signiﬁcant  difference  in
verall  diagnostic  value  between  MRI  and  FDG-PET/CT  in
ervical  lymph-node  extension  assessment  [33]. A  recent
rospective  study  (n  =  114  patients)  comparing  FDG-PET/CT
nd  MRI  or  CT  found  signiﬁcantly  better  sensitivity  and  speci-
city  in  FDG-PET/CT  in  detecting  both  ipsilateral  (Se  =  88%
s.  70%)  and  contralateral  (Se  =  52%  vs.  36%)  lymph-node
etastasis.  Negative  FDG-PET/CT  ﬁndings,  however,  do  not
ule  out  lymph-node  invasion  [34].
Imaging  assessment  of  metastatic  adenopathy  from
squamous  cell  carcinoma  without  known  primary:
SFORL  guidelines
Contrast-enhanced  cervicothoracic  CT  and  FDG-
PET/CT  should  be  performed  as  part  of  the  diagnostic
assessment  of  metastatic  adenopathy  from  carcinoma
without  known  primary.  Imaging  should  ideally  precede
endoscopic  assessment  and  biopsy  (Grade  B).
In  suspected  adenopathy,  if  cytologic  and  clinical  ﬁndings
oint  to  lymph-node  metastasis  from  a  squamous  cell  car-
inoma  not  found  on  initial  assessment,  FDG-PET/CT  should
ogically  precede  panendoscopy  with  biopsies  associated  to
psilateral  tonsillectomy  [35]. Performing  endoscopy  as  a
econd  step  has  the  double  advantage  of  not  creating  arti-
acts  affecting  FDG-PET/CT  interpretation  and  of  guiding
iopsy.  FDG-PET/CT  performed  before  panendoscopy  when
ross-sectional  imaging  by  CT  or  MRI  was  negative  located
9%  of  primary  tumors  in  Miller  et  al.’s  series  [36]; associat-
ng  FDG-PET/CT  to  panendoscopy  led  to  a  detection  rate  of
5%.  When  both  examinations  were  negative,  the  tumor  was
ound  during  follow-up  in  fewer  than  6%  of  cases  [36]. Series
eported  in  the  literature  do  not  seem  to  be  easily  compara-
le;  it  appears,  however,  that  the  sensitivity  of  FDG-PET/CT
anges  between  27  and  87.5%,  compared  to  25—43.7%  for
onventional  imaging,  and  that  the  positive  predictive  value
f  FDG-PET/CT  ranges  between  57  and  77%,  compared  to
2—75%  for  CT  [37—40].
Initial  staging  of  squamous  cell  carcinoma  of  the  oral  cavity,  lary
Time  to  treatment:  SFORL  guidelines
Staging  should  be  organized  as  quickly  as  possible,
so  as  to  initiate  treatment  early.  The  interval  between
the  ﬁrst  consultation  with  the  team  that  is  to  manage
the  patient  and  the  collection  of  data  for  decision-
making  and  organization  of  treatment  should  be  kept
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(as  short  as  possible:  ideally  2  weeks,  and  not  longer
than  4  weeks  (professional  consensus).
Time  to  treatment
The  literature  on  time  to  treatment  focuses  mainly  on
delayed  diagnosis  due  to  patient  or  health-care  professional
related  factors  (delayed  specialist  referral)  or  on  the  inter-
val  between  diagnosis  and  implementation  of  treatment,
mainly  in  the  case  of  radiation  therapy,  and  consists  of  ret-
rospective  cohort  studies  or  meta-analyses.
Wyatt  et  al.,  in  a  theoretical  study  of  the  probability
of  tumor  control  by  radiation  therapy  according  to  cell
clone  doubling  time  on  the  Poisson  model,  estimated  that
each  extra  week’s  delay  before  treatment  initiation  reduced
tumor  control  by  1%  [41]. Waaijer  et  al.  compared  CT  scans
for  staging  and  for  radiation  therapy  landmarking  in  13
patients,  with  a  mean  interval  of  56  days  between  the  two;
the  mean  increase  in  tumor  volume  was  70%,  impacting  stag-
ing  in  23%  of  patients  [42]. Chen  et  al.’s  meta-analysis  found
an  increased  relative  risk  of  local  recurrence  after  radiation
therapy  of  1.15  per  month  between  diagnosis  and  treatment
initiation  (95%CI:  1.02—1.29)  [43], and  Huang  et  al.’s  meta-
analysis  of  4  studies  found  a  1.17  increase  in  RR  of  local
recurrence  (95%CI:  0.96—1.44)  for  an  interval  greater  than
1  month  [44].
Fortin  et  al.’s  retrospective  study  found  increased  risk
of  local  or  regional  recurrence  and  reduced  survival  when
the  interval  to  initiation  of  radiation  therapy  exceeded  40
days  [45]. This  ﬁnding  is  in  contradiction  with,  for  example,
g
d
Level  of  evidence  provide  by  the  literature  
EXPLANATION  
LEVEL  1  
Randomized  comparative  trial  with  strong  power
Meta-analysis  of  randomized  comparative  trials  
Decision analysis  based  on  well-conducted  studies
LEVEL  2  
Randomized  comparative  trial  with  weak  power
Well-conducted  non-randomized  comparative  trial  
Cohort study
LEVEL  3
Case-control  study
Retrospective  comparative  trial
LEVEL  4  
Comparative  study  with  signiﬁcant  bias
Retrospective  study
Case  series
Descriptive  epidemiological  study  (transversal,  longitudinal)  
Any other  publication  (Expert  opinion,  etc.)
No publicationnx  and  pharynx  43
audell  et  al.’s  study,  which  found  no  impact  of  interval  to
nitiation  of  radiation  therapy  on  results  [46]. Schlienger,  in
 literature  review,  retrieved  ﬁve  studies  reporting  negative
mpact  of  late  treatment  initiation  and  eight  reporting  none;
hey  recommended  a  ceiling  of  2  weeks  for  initial  staging
47].
onclusion
ocoregional  extension  assessment  in  head  and  neck  can-
er  should  determine  patients’  individual  tumor  stage  and
esection  possibilities.  It  should  then  be  discussed,  in  the
ight  of  the  general  health  assessment  and  remote  exten-
ion  assessment,  in  the  multidisciplinary  team  meeting
o  determine  a  treatment  option  in  line  with  the  vali-
ated  guidelines,  which  will  be  presented,  along  with  any
lternatives,  in  a  dedicated  consultation  with  the  patient.  In
ollaboration  with  the  patient’s  family  physician,  the  treat-
ent  proposal  should  be  made  as  described  in  the  French
ealth  authority  (HAS)  circular  DHOS/SDO/2005/101  (Febru-
ry  22,  2005)  concerning  care  organization  in  oncology  and
ational  guidelines  for  the  implementation  of  the  cancer
iagnosis  disclosure  system  in  health  establishments  [48].
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
ppendix A. Correspondence between levels
f  evidence in the literature and guideline
rades (from the French health authority
HAS) guide to literature analysis and
uideline grading, January 2000,  in turn
erived from the Sackett scoring system)
Strength  of  recommendation
RECOMMENDATION
GRADE  A
Good  scientiﬁc  evidence
GRADE  B
Fair  scientiﬁc  evidence
GRADE  C
GRADE  DLow  level  of  scientiﬁc  evidence
Professional  consensus
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